EarlyNarratives
Pricing
Start free trialSign in
Start free trialSign in
Today's Brief

Updated daily.

Get the free BIOTECH brief in 5 minutes.

A free daily and weekly email that tells you what changed, what is noise, and where to verify it at the source.

  • Start with the short list before you open another feed.
  • See what is continuing versus what is only today's spike.
  • Open the original sources in one click when you want to verify.
Free daily + weekly email
Read today's brief

Free by email: Today’s Brief (daily) + This Week’s Brief (weekly). Upgrade later for archive, alerts, search, exports, API, and workflow.

Get tomorrow's brief by email

One field, compact consent, daily + weekly by default.

Free by email: Today’s Brief.
Please confirm consent to continue.
Add your email to continue.
How it worksOpen featured signal
What you would receive
Featured now

Travere secures first FDA approval for rare kidney disease drug Filspari

Travere Therapeutics has achieved FDA approval for Filspari, the first treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. This approval fo...

Why now: The FDA approval follows a recent three-month review extension and a challenging phase 3 trial outcome.

  • biopharmadive.com
    BioPharma Dive
  • pharmaphorum
    Travere claims first FDA OK in rare kidney disease FSGS
  • Fierce Pharma (All)
    From a negative phase 3 readout and a seemingly tightening regulatory climate to a grueling three-month review extension, Travere has defied the odds, securi...
All source links included.
Open today's sampleBrowse signals
Read today's briefBrowse signals
Today’s strongest item first

The homepage leads with an editorially featured signal alongside the open brief, while current signals stay open across the site.

Proof, not boilerplate

3 real source links are already visible in today’s public example.

Free brief before upgrade

Get the daily + weekly brief by email first. Upgrade only if you need archive, alerts, search, exports, API, and deeper workflow tools.

What lands in your free brief

Start with the brief, then drill down only on the items that matter.

Briefing item

Astellas to close Seattle stem cell therapy unit with layoffs

Astellas is shutting down the Seattle site of its stem cell therapy unit, Universal Cells, impacting approximately 50 to 55 employees. The closure marks a significant reduction in the company's stem cell therapy operations in the region.

Why now: The announcement is recent, reflecting current strategic decisions by Astellas.

CurrentSource diversity aware
Sources: 2
See details ->
Briefing item

Advances in single-cell and organoid models enhance cancer drug response prediction

Recent studies showcase innovative platforms to improve prediction of cancer drug responses.

Why now: Recent benchmarking reveals strengths and gaps in current single-cell drug response models.

CurrentSource diversity aware
Sources: 3
See details ->
Briefing item

Early-career biotech scientists seek advice on job market challenges

Several early-career scientists with PhDs and postdoctoral experience are sharing their struggles entering the biotech industry. They report difficulties securing positions despite relevant skills, geographic constraints, and concerns about overqualification.

Why now: Job market difficulties are current and ongoing for early-career biotech scientists.

CurrentSource diversity aware
Sources: 2
See details ->
How it works

Built to save you time while keeping every key point easy to verify.

Read widely

News, social, dev channels, and primary sources.

Remove duplicates

Filter rewrites, SEO clones, and repeated takes.

Group what belongs together

So you see one story, not 20 scattered posts.

Deliver the briefing

A daily scan + drill-down with source links.

See Methodology
Start free, upgrade only if you need more

Start with the free brief if you want the signal first, not an hour of scrolling. It gives you the short list, the context, and the source links in one pass.

Upgrade later only if you need memory, alerts, archive, exports, API, and recurring workflow for ongoing research work.

Why people start with the free brief
Daily brief

The 5-minute version of what genuinely changed since yesterday.

Momentum over time

See what is building, peaking, or fading across days and weeks.

Source links included

Jump to the originals when you need to verify a claim fast.

Free daily + weekly emailUpgrade only when you need full drill-down
Get the free brief
See pricingThis Week’s Brief
Product tour

A short walkthrough of the BIOTECH dashboards.